文献速递瓣膜外科

首次外科主动脉瓣置换:荷兰心脏登记全国趋势与结局

First-time surgical aortic valve replacement: nationwide trends and outcomes from The Netherlands Heart Registration.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该研究基于荷兰心脏登记数据库,报告2007至2018年成人孤立性首次外科主动脉瓣置换(SAVR)的数量与结局。共纳入17142例,生物瓣占77.9%、机械瓣占21.0%;120天死亡率从2007年3.3%降至2018年0.7%,调整后10年生存率72.4%、10年免于再干预率98.1%。

要点

  • 2007至2018年荷兰SAVR患者年龄与风险谱下降,生物瓣使用占77.9%。
  • 120天死亡率从2007年3.3%降至2018年0.7%。
  • 调整后10年生存率72.4%,10年免于再干预率98.1%。

核心结论

  • 2007至2018年间接受SAVR的患者年龄与风险谱下降,尤以生物瓣治疗者明显;120天死亡率随时间下降。
  • 当前接受SAVR的患者120天死亡率风险低于1%,10年免于瓣膜相关再干预率高于95%。

研究设计与样本

  • 使用荷兰心脏登记数据库,报告2007至2018年成人孤立性首次SAVR手术的数量与结局。
  • 共纳入17142例手术,其中生物瓣占77.9%、机械瓣占21.0%。
  • 中位随访76个月(IQR 53-111)。

主要发现

  • 中位logistic EuroSCORE I从4.6(IQR 2.4-7.7)降至4.0(IQR 2.6-6.0)。
  • 120天死亡率从2007年3.3%降至2018年0.7%。
  • 调整年龄、EuroSCORE I和体表面积后,10年生存率为72.4%,调整后10年免于再干预率为98.1%。
  • 60岁以下患者中,生物瓣与机械瓣调整后10年生存率分别为89.7%与91.9%(P=0.25),无显著差异。
  • 60岁以下患者中,生物瓣与机械瓣调整后10年免于再干预率分别为90.0%与95.9%(P<0.01),差异显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to describe trends and outcomes for patients undergoing surgical aortic valve replacement (SAVR) in the Netherlands. METHODS: The Netherlands Heart Registration database was used to report the number and outcomes of isolated, primary SAVR procedures performed from 2007 to 2018 in adult patients. RESULTS: A total of 17 142 procedures were included, of which 77.9% were performed using a biological prosthesis and 21.0% with a mechanical prosthesis. Median logistic EuroSCORE I decreased from 4.6 [interquartile range (IQR) 2.4-7.7] to 4.0 (IQR 2.6-6.0). The 120-day mortality decreased from 3.3% in 2007 to 0.7% in 2018. The median duration of follow-up was 76 months (IQR 53-111). Ten-year survival, when adjusted for age, EuroSCORE I and body surface area, was 72.4%, and adjusted 10-year freedom from reinvervention was 98.1%. Additional analysis for patients under the age of 60 showed no difference between patients treated with a biological or mechanical prosthesis in adjusted 10-year survival, 89.7% vs 91.9±%, respectively (P = 0.25), but a significant difference in adjusted 10-year freedom from reintervention, 90.0±% vs 95.9%, respectively (P < 0.01). CONCLUSIONS: Between 2007 and 2018, age and risk profile of patients undergoing SAVR decreased, especially for patients treated with a biological prosthesis. The 120-day mortality decreased over time. Patients undergoing SAVR nowadays have a risk of 120-day mortality of <1% and 10-year freedom from valve-related reintervention of >95%.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Daeter EJ, de Beaufort HWL, Roefs MM, et al. First-time surgical aortic valve replacement: nationwide trends and outcomes from The Netherlands Heart Registration. Eur J Cardiothorac Surg. 2024. PMID: 38730543. doi:10.1093/ejcts/ezae177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。